The Market for Pharmaceutical Contract Manufacturing will reach $84.0Bn in 2020

Monday 31 October 2016, Amsterdam

Market Research Report Press Release A new report, now available on ASDReports, forecasts that overall pharmaceutical contract manufacturing market will achieve revenues of $84.0 billion in 2020, at a compound annual growth rate of 6.4% from 2015 to 2020. The market is expected to continue to grow from 2016 to 2026 as the pharmaceutical companies are strategically outsourcing services. That revenue prediction and others appear in Pharma Leader Series: Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026.

This updated study discusses market-leading companies, the strategies they have employed to grow in the past few years, and how they will continue to expand to 2026. The study analyses deals, commercial prospects and financial performances of 30 leading pharmaceutical CMOs in the following regions:
  • North America
  • Europe
  • Japan
  • China
  • India                                                                                                           
In particular it discusses revenue prospects, including forecasts, analysis of the operational performance and forecast profitability of some leading CMOs. The new investigation also discusses forces driving and restraining individual firms and provides competitive intelligence for companies operating in the pharmaceutical contract manufacturing market. It also examines opportunities and challenges for individual firms and strategies that can be employed to maximise performance from 2016 to 2026.

In 2015, out of all the contract manufacturing services, API Manufacturing continues to hold the largest share of the total market revenue like last year. In parallel, FDF manufacturing shows the fastest growth. Geographically, developed countries hold the maximum share of the outsourcing. North America holds the largest market share of the industry. This study shows that pharmaceutical companies will continue to outsource mainly in developed countries. However, the Indian and Chinese markets are growing at a faster rate as compared to the CMO market in developed countries.

Shruti Tayal, a pharmaceutical industry analyst said:

“Within pharmaceutical contract manufacturing, active pharmaceutical ingredient (API) continues to form the largest revenue producing segment in 2015. Final dosage form (FDF) continues to expand at the fastest rate from 2016 to 2026. Leading CMOs will capture most of the customers owing to integrated service offerings, also benefiting from consolidation in that pharma service industry. Pharmaceutical companies will continue to outsource some manufacturing operations to save time and money in emerging regions such as India, China and Latin America. Those firms will increase competition in the developing national CMO markets. India and China are already prominent for contract production of APIs and FDFs for domestic use and export. That trend will continue, with opportunities also remaining for CMO operations in North America, Europe, Japan and other established markets, especially for high-value biological drug products”.
Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026

Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026

Publish date : September 2016
Report code : ASDR-291184
Pages : 317

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News